Pacific Biosciences' Q1 Revenues Better Than Anticipated, Down Sequentially | GenomeWeb

NEW YORK (GenomeWeb News) – Pacific Biosciences reported after the close of the market Tuesday first-quarter revenues of $10 million, beating Wall Street's consensus estimate of $7.1 million.

The revenues compared to $270,000 in revenue for the first quarter of 2011, before the firm launched its PacBio RS system. The Q1 2012 revenues compare to fourth-quarter 2011 revenues of $12.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: weighting scheme increases GWAS power, and more.

Marc Tessier-Lavigne is to be the next president of Stanford University.

Walgreens has given Theranos 30 days to fix its lab issues, the Wall Street Journal reports.

Journals and research funding agencies pledge to enable the sharing of Zika virus research.

Feb
25
Sponsored by
Omicia

This webinar will demonstrate how ACMG's recommended variant scoring and classification rules may be applied to standardize reporting on sequencing test results within and across institutions. 

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies. 

Mar
17
Sponsored by
Qiagen

This webinar will discuss Qiagen's approach to address two challenges facing NGS in the clinical research setting: lack of seamless workflow for routine clinical research use and truly relevant content to guide clinical research activities.